Oncolytics Biotech Shares PromisingCancer ResearchUpdates

Oncolytics Biotech Inc. provided promising updates on their cancer research and clinical studies during their Q1 2024 earnings call. The company outlined plans to begin registrational track studies for their lead indications in breast and pancreatic cancer.

author-image
Trim Correspondents
New Update
Oncolytics Biotech Shares PromisingCancer ResearchUpdates

Oncolytics Biotech Shares PromisingCancer ResearchUpdates

Oncolytics Biotech Inc. (NASDAQ: ONCY) provided promising updates on their cancer research and clinical studies during their first quarter 2024 earnings call held on May 9, 2024. The company outlined plans to begin registrational track studies for their lead indications in breast and pancreatic cancer, positioning them to bring their proprietary immunotherapeutic product candidate, pelareorep (pela), to patients as quickly as possible.

Why this matters: The development of effective cancer treatments has far-reaching implications for public health, as cancer remains one of the leading causes of death worldwide. Advancements in immunotherapy, such as pelareorep, could lead to improved patient outcomes and increased life expectancy, ultimately reducing the economic and social burdens of cancer on individuals and society.

Dr. Matt Coffey, Chief Executive Officer of Oncolytics Biotech, emphasized the company's mission, stating, "Our mission is to improve the lives of people with cancer by bringing our proprietary immunotherapeutic product candidate pelareorep to patients as quickly as possible." Pela is a highly unique immunotherapy candidate that selectively replicates in tumors, introducing double-stranded RNA into cancer cells, generating, recruiting, and training immune cells to identify and kill cancer cells.

Clinical trials have demonstrated meaningful clinical responses with pela, showing favorable comparisons to historical controls. Pela has also shown synergies with multiple cancer treatments, including chemotherapy, immune checkpoint inhibitors, and CAR T cell therapy. Dr. Coffey further highlighted the company's progress, stating, "We are building the necessary foundation to begin registrational track studies for both of these indications for which there is an urgent need for new or alternative therapies."

Oncolytics Biotech believes it has sufficient cash to achieve its critical objectives through 2024. The company plans to provide updates on its breast cancer program, including the GOBLET pancreatic cancer cohort expansion and anal cancer cohort. Initial plans for the registrational track pancreatic cancer study will also be shared. Chief Financial Officer Kirk Look will provide financial updates during the earnings call.

The promising updates shared by Oncolytics Biotech Inc. during their first quarter 2024 earnings call highlight the potential of their lead immunotherapeutic candidate, pelareorep, in treating breast and pancreatic cancer. With plans to begin registrational track studies and sufficient cash to achieve critical objectives, the company is well-positioned to advance their mission of improving the lives of cancer patients by bringing innovative therapies to market.